High Rate of HIV-1 Drug Resistance in Antiretroviral Therapy-Failure Patients in Liaoning Province, China.
PMID: 35229630
2022
AIDS research and human retroviruses
Abstract: K65R (29.69%), M184V (28.52%) were the most common NRTIs resistance mutations.
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
PMID: 33649107
2021
Antimicrobial agents and chemotherapy
Introduction: Likewise, cases of failure with emergent M184V and R263K were reported for DTG-plus-lamivudine dual therapy in the clinical trials GEMINI and ACTG5353.
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies.
Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49),
High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Abstract: Of the 27 viraemic isolates successfully genotyped, 20 (74.1%) carried DR mutations; most frequent were M184VI (55.6%), K103N (37.1%), thymidine analog mutations (29.6%), Y181CY (22.2%).
Result: FTC and 3TC were also predicted with high-level DR (55.6%), which however is associated with a higher fitness cost due to the point mutation M184V.
Result: For NRTIs, these were M184VI (55.6%), T215SNY (22.2%), and K65R (18.5%).
Table: M184V
Discussion: In subgroup analysis of DR, most widespread DRMs among failing patients were 3TC-resistance M184V and NVP-resistance
Low Frequency of Integrase Inhibitor Resistance Mutations Among Therapy-Naive HIV Patients in Southeast China.
PMID: 33679129
2021
Drug design, development and therapy
Abstract: Two samples harbored the T215S, M184V and K70E mutations related to nucleoside RTIs (NRTIs).
Result: In one participant, two NRTIs-resistance mutations (M184V, K70E) were observed.
Result: The M184V mutation can contribute to resistance if present along with other major resistance mutations high level resistance to lamivudine (3TC) and emtricitabine, and low-level resistance to didanosine and abacavir.
Table: M184V
Dolutegravir response in antiretroviral therapy naive and experienced patients with M184V/I: Impact in low-and middle-income settings.
PMID: 33722682
2021
International journal of infectious diseases
Abstract: DISCUSSION: Despite high prevalence of M184V/I in antiretroviral therapy (ART) experienced patients, DTG treatment outcomes will likely not be adversely affected by this mutation.
Abstract: DTG-based regimens have to great extent been effective at maintaining viral suppression in treatment experienced PLWH carrying M184V/I.
Abstract: High genetic barrier to the development of resistance associated with DTG and progressive viral suppression in patients switched to DTG-based therapy with M184V/I, may encourage better DTG outcomes and help in curbing increasing levels of HIV drug resistance in LMICs.
Abstract: Lamivudine and emtricitabine associated M184V/I mutation is highly prevalent in PLWH and the majority of HIV infected individuals receiving DTG regimen
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
PMID: 33855355
2021
The Journal of antimicrobial chemotherapy
Abstract: Resuming the same 2-DR 7 days a week led to viral resuppression in three patients, whereas the M184V mutation emerged in one patient, leading to ART modification.
A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells.
Abstract: In this study, we established such an assay and validated it using 346 primary HIV-1 isolates from patients enrolled in the Zurich Primary HIV Infection study (ZPHI) and two control viruses, HIV-1 JR-CSFWT and HIV-1 JR-CSFK65R_M184V.
Result: Furthermore, HIV-1 JR-CSFWT replicates at a higher efficiency when compared to the replication kinetics of HIV-1 JR-CSFK65R_M184V (Figure 3D,E).
Result: HIV-1 JR-CSFK65R_M184V replicated more than 3-logs lower than HIV-1 JR-CSFWT.
Result: Interestingly, one primary HIV-1 isolate had a lower replication capacity than HIV-1 JR-CSFK65R_M184V.
Result: It has been previously shown that the K65R mutation reduces replication capacity up to 55% compared to the wildtype virus, but when paired with the
Comparison of the Virological Response According to the Antiretroviral Regimens in Peruvian HIV Patients Who Presented the M184V Mutation in Two National Hospitals During the Years 2008 to 2019.
PMID: 33076683
2021
AIDS research and human retroviruses
Abstract: Conclusions: In patients with HIV and the M184V mutation, the PI + INI ART has shown a greater decrease in control VL and, thus, a good virological response.
Abstract: Introduction: In patients with HIV in antiretroviral treatment (ART) and virological failure to the first-line regimen, establishing a therapeutic regimen after having identified the M184V mutation, which confers ART resistance, represents a dilemma.
Abstract: Methods: A retrospective cohort study was developed based on the information of the HIV program participants with the M184V mutation.
Abstract: Objective: To compare the virological response of the therapeutic regimens prescribed to patients with HIV who presented the M184V mutation in two national hospitals in Lima, Peru, during the y
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Abstract: CONCLUSIONS: In this real-world cohort, the majority of whom had virus with the M184V/I and >= 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA >= 50 copies/mL in 18%.
Abstract: Historical genotypes indicated that all had an M184V/I, and 23 (59%) had an M184V/I and >= 1 additional NA mutation.
Introduction: In both the GEMINI and TANGO studies, patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) resistance include those with M184V/I and integrase strand transfer inhibitor (INSTI) resistance were excluded.
HIV mutation literature information.
PMID: 
2022
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT